Founded in 2000, Metabolon is an emerging technology company developing proprietary analytical methods and software for biomarker discovery using metabolomics. We conduct a fee-for-service business using metabolomics in pharmaceutical, biotech, agriculture, cosmetic and consumer product research. In addition, we are using our metabolomics platform to develop diagnostics for cancer, amyotropic lateral sclerosis (ALS, or Lou Gehrig's disease), and metabolic diseases. Metabolon's goal is to establish its technology as the standard in biomarker discovery in healthcare and related sciences.
Metabolon's commercial platform was launched in 2004 following years of pioneering work in software development and mass spectrometry engineering. Our technology utilizes a global and unbiased view of the human metabolome. The result is the identification of hundreds of named metabolites that are analyzed for their impact on well-known and documented biochemical pathways. We have filed pioneering method patents on the use of metabolomics for drug discovery, disease treatment, and diagnosis. Our first patent was issued in 2006 in the field of ALS. More than 60 additional methods and biomarker patents have been filed and are in various stages of prosecution.
Metabolon is located in Research Triangle Park, North Carolina, and is venture funded by investors including Sevin Rosen Funds, Aurora Funds, Trelys Funds, and Harris & Harris Group. – less–ZoomInfo